ReviewOrphanet journal of rare diseases2025
Revisiting hemoglobin constant spring: molecular insights, pathophysiological mechanisms, and clinical perspectives.
Review in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHemoglobin Constant Spring (Hb CS) is an α-globin variant predominantly found in Southeast Asian populations. Compound heterozygosity of Hb CS with α-thalassemia results in a spectrum of chronic hemolytic anemia. Recent advances in cellular therapy, particularly gene editing approaches currently under in-vitro investigation, offer potential new avenues for treatment in patients with severe phenotypes. MAIN BODY: This review discusses the molecular basis, pathophysiology, clinical manifestations, and current management strategies of Hb CS. The condition arises from a point mutation in the termination codon of the HBA2 gene (HBA2:c.427T > C; p.Ter143Gln), leading to unstable mRNA, defective hemoglobin synthesis, and red blood cell membrane abnormalities. The clinical presentation of Hb H/Constant Spring disease and related genotypes ranges from mild anemia to severe hemolysis. In cases of homozygous Hb Constant Spring, affected fetuses may present with hydrops fetalis and severe intrauterine anemia; however, clinical improvement is typically observed after birth, with anemia often stabilizing to a milder form during infancy or early childhood. Management strategies vary from observation in mild cases to regular blood transfusions in more severe cases. Emerging gene editing techniques, including prime editing, represent promising therapeutic modalities under preclinical investigation.
conclusionHb CS is characterized by complex molecular mechanisms and a broad clinical spectrum. This review aims to provide a comprehensive overview to support improved clinical management of affected individuals and to explore future directions in therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.